HER2 overexpressing metastatic breast cancer (Q34677844)

3 August 2017

1 reference

title

HER2 overexpressing metastatic breast cancer (English)

1 reference

3 August 2017

1 reference

David R Spigel

1

1 reference

3 August 2017

Harold J Burstein

series ordinal

2

1 reference

3 August 2017

publication date

1 April 2002

1 reference

Current Treatment Options in Oncology

3 August 2017

published in

1 reference

3 August 2017

volume

3

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

163-174

1 reference

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

3 August 2017

cites work

1 reference

12 December 2020

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

12 December 2020

Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models

1 reference

12 December 2020

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

1 reference

12 December 2020

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

12 December 2020

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

12 December 2020

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer

1 reference

12 December 2020

Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients

1 reference

12 December 2020

Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle

1 reference

12 December 2020

Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.

1 reference

12 December 2020

10.1007/S11864-002-0062-8

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1046675423

0 references

Fatcat ID

release_wwrvknnk3jgsbhi46biwpz2fdm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wwrvknnk3jgsbhi46biwpz2fdm

24 November 2022

mapped directly with Wikidata item

1 reference